Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's total debt is ยฃ12.61 Billion. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2024-12-31 | ยฃ11.42 B | 264.04% |
2023-12-31 | ยฃ3.13 B | 2.29% |
2022-12-31 | ยฃ3.06 B | 2.13% |
2021-12-31 | ยฃ3.00 B | 139.3% |
2020-12-31 | ยฃ1.25 B | 145.01% |
2019-12-31 | ยฃ0.51 B | 724.61% |
2018-12-31 | ยฃ62.16 M | -69.24% |
2017-12-31 | ยฃ0.20 B | 668.97% |
2016-12-31 | ยฃ26.27 M | -75.24% |
2015-12-31 | ยฃ0.10 B | 40.48% |
2014-12-31 | ยฃ75.53 M | 213% |
2013-12-31 | ยฃ24.13 M | -56.01% |
2012-12-31 | ยฃ54.85 M | -42.63% |
2011-12-31 | ยฃ95.6 M | -62.82% |
2010-12-31 | ยฃ0.25 B | 55.61% |
2009-12-31 | ยฃ0.16 B | -44.45% |
2008-12-31 | ยฃ0.29 B | 121.14% |
2007-12-31 | ยฃ0.13 B | -1.88% |
2006-12-31 | ยฃ0.13 B | -44.53% |
2005-12-31 | ยฃ0.24 B | 52.72% |
2004-12-31 | ยฃ0.16 B | -1.2% |
2003-12-31 | ยฃ0.16 B | 21.43% |
2002-12-31 | ยฃ0.13 B | -25.66% |
2001-12-31 | ยฃ0.18 B | -1.56% |
2000-12-31 | ยฃ0.18 B | -4.64% |
1999-12-31 | ยฃ0.19 B | -25.24% |
1998-12-31 | ยฃ0.25 B | -12.2% |
1997-12-31 | ยฃ0.29 B | 40.78% |
1996-12-31 | ยฃ0.20 B |
Company | Total debt/th> | differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | ยฃ44.92 B | 256.00% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | ยฃ28.22 B | 123.72% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | ยฃ37.55 B | 197.62% | ๐บ๐ธ USA |
![]() Sanofi SNY | ยฃ16.68 B | 32.26% | ๐ซ๐ท France |